- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nanobiotix S.A.
Industry Sector: HealthTechnology
CEO: Laurent Lévy, PhD
Number Of Employees: 108
Enterprise Value: $150,122,344
PE Ratio: -3.88
Exchange/Ticker 1: Euronext Paris:NANO
Exchange/Ticker 2: NASDAQ:NBTX
Latest Market Cap: $153,059,010
BioCentury | Sep 7, 2023
Management Tracks
Biogen taps former Genentech exec Grogan as head of research
Plus: Arjona Ferreira named CMO at Organon, and updates from Convergent, Purespring, Nanobiotix, Enzo, FibroGen, Engitix and more
BioCentury | Jul 10, 2023
Deals
July 10 Quick Takes: Astellas licenses 4D’s AAV vector
Plus: J&J partners with Nanobiotix and updates from CMS, WuXi, BeiGene and more
BioCentury | May 26, 2022
Management Tracks
Zai, BMS veteran Fu joins Frazier as partner
Plus OrbiMed alum Khuong joins Catalio Capital, Warma named CEO of Genexine and more
BioCentury | Nov 4, 2021
Finance
Perceptive-backed LianBio readies for its next act
After $325M IPO, seven deals, and addition of a China GM, cross-border play prepares to start pivotal studies
BioCentury | Jul 13, 2021
Management Tracks
Berkley joins AbCellera as CBO; plus Genespire, Corcept, Shoreline and more
Antibody discovery company AbCellera Biologics Inc. (NASDAQ:ABCL) hired Neil Berkley as CBO. Berkley joins from Halozyme Therapeutics Inc. (NASDAQ:HALO) where he was VP, head of business
BioCentury | Jun 3, 2021
Management Tracks
Gilde builds public markets expertise with Muijrers hire; plus Nanobiotix, Shattuck, Ichnos, Generate, Alpine and more
Joep Muijrers has joined Gilde Healthcare to lead the Dutch firm’s venture and growth capital fund. Muijrers is a veteran of PureTech Health plc (LSE:PRTC; NASDAQ:PRTC), where he served as
BioCentury | May 12, 2021
Deals
May 11 Quick Takes: $830M for tumor profiler Caris; plus Nuvalent’s $135M series B, Ginkgo’s $2.5B SPAC and updates from Adaptive, LianBio-Nanobiotix, Phico, Laevoroc
Sixth Street has made its third investment in molecular profiling company Caris Life Sciences Inc., leading a $830 million round at a postmoney valuation of $7.8 billion. The investment comes less
BioCentury | Jul 1, 2019
Company News
Management Tracks: BioCryst hires its first CBO; plus ObsEva, Veracyte and more
BioCentury | Jan 18, 2019
Company News
MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets
Items per page:
1 - 10 of 54